ArticlePharmacology research & perspectives2022
The signaling and selectivity of α-adrenoceptor agonists for the human α2A, α2B and α2C-adrenoceptors and comparison with human α1 and β-adrenoceptors.
Article in Pharmacology research & perspectives, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 25 citations in OpenAlex.
- Targeting GCell reports. Medicine · 2026Article
- A Review of Alpha-2 Adrenergic Agents Implicated in Opioid Use Disorder.ACS chemical neuroscience · 2026Review
- Acute fentanyl and xylazine co-exposure uniquely increase the excitability of dopamine type 2 receptor-expressing striatal medium spiny neurons.Journal of neurophysiology · 2026Article
- Peculiarities of the Effect of Selective of α2A/D-Adrenoreceptor Blockade on the Isolated Rat Heart.Bulletin of experimental biology and medicine · 2026Article
- Brimonidine Beyond a Single Specialty: Pharmacological Profile, Dermatologic Applications, and Advances in Drug Delivery Systems.International journal of molecular sciences · 2026Review
- In Vitro Pharmacology of Mitragynine at α-Adrenoceptors.ACS chemical neuroscience · 2025Article
- The locus coeruleus maintains core body temperature and protects against hypothermia during dexmedetomidine-induced sedation.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Successful treatment of five cases of catatonia treated with guanfacine without ECT: a case series from a psychiatric hospital in Japan.BMC psychiatry · 2025Article
- Structure-guided engineering of snake toxins for selective modulation of adrenergic and muscarinic receptors.Nature communications · 2025Article
- Additive Effects of Clonidine Used in Propofol Sedation in Colonoscopy.Anesthesiology and pain medicine · 2025Article
- A stratified precision medicine trial targeting αNature. Mental health · 2025Article
- Comprehensive mini-review: therapeutic potential of cannabigerol - focus on the cardiovascular system.Frontiers in pharmacology · 2025Review
- Novel Scaffold Agonists of the αMolecules (Basel, Switzerland) · 2024Article
- Signalling of Adrenoceptors: Canonical Pathways and New Paradigms.Handbook of experimental pharmacology · 2024Review
- Asthma and COPD: A Focus on β-Agonists - Past, Present and Future.Handbook of experimental pharmacology · 2024Review
- Alpha-2-adrenergic agonists reduce resting energy expenditure in humans during external cooling.Temperature (Austin, Tex.) · 2024Article
- Adrenoceptors: Receptors, Ligands and Their Clinical Uses, Molecular Pharmacology and Assays.Handbook of experimental pharmacology · 2024Review
- Dexmedetomidine modulates neuronal activity of horizontal limbs of diagonal band via α2 adrenergic receptor in mice.BMC anesthesiology · 2023Article
- The signaling and selectivity of α-adrenoceptor agonists for the human α2A, α2B and α2C-adrenoceptors and comparison with human α1 and β-adrenoceptors.Pharmacology research & perspectives · 2022Article
- The αASN neuroArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
α2-adrenoceptors, (α2A, α2B and α2C-subtypes), are Gi-coupled receptors. Central activation of brain α2A and α2C-adrenoceptors is the main site for α2-agonist mediated clinical responses in hypertension, ADHD, muscle spasm and ITU management of sedation, reduction in opiate requirements, nausea and delirium. However, despite having the same Gi-potency in functional assays, some α2-agonists also stimulate Gs-responses whilst others do not. This was investigated. Agonist responses to 49 different α-agonists were studied (CRE-gene transcription, cAMP, ERK1/2-phosphorylation and binding affinity) in CHO cells stably expressing the human α2A, α2B or α2C-adrenoceptor, enabling ligand intrinsic efficacy to be determined (binding K
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.